Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets
Nektar Therapeutics (NKTR) has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, after U.S. market close.
Rhea-AI Summary
Nektar Therapeutics (NKTR) has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, after U.S. market close. The company's President and CEO, Howard Robin, will lead a conference call at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time to discuss the results. Investors can access the audio-only webcast through the company's investor relations website at ir.nektar.com. The webcast replay will be available until June 8, 2025. Pre-registration is required for conference call participation.
Details
News Market Reaction – NKTR
The recorded move for NKTR in the trading session of this news was -3.60%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. The web broadcast of the conference call will be available for replay through June 8, 2025.
To access the conference call, please pre-register at Nektar Earnings Call Registration. All registrants will receive dial-in information and a PIN allowing them to access the live call.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in
Contacts:
For Investors:
Ahu Demir, Ph.D.
LifeSci Advisors, LLC
ademir@lifesciadvisors.com
212-915-3820
For Media:
Madelin Hawtin
LifeSci Communications 603-714-2638
mhawtin@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-to-announce-financial-results-for-the-first-quarter-on-thursday-may-8-2025-after-close-of-us-based-financial-markets-302443436.html
SOURCE Nektar Therapeutics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.